𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Driving ability in Parkinson's disease: Current status of research

✍ Scribed by Ester I. Klimkeit; John L. Bradshaw; Judith Charlton; Rene Stolwyk; Nellie Georgiou-Karistianis

Publisher
Elsevier Science
Year
2009
Tongue
English
Weight
191 KB
Volume
33
Category
Article
ISSN
0149-7634

No coin nor oath required. For personal study only.

✦ Synopsis

Guidelines for assessing fitness to drive in individuals with neurodegenerative disorders, such as Parkinson's disease (PD), are subjective. It is therefore timely to review the current status of the literature not only for health professionals who are required to assess fitness to drive, but also for the development of future research directions. This review, in the context of PD, outlines the complex changes in driving behaviours, motor vehicle crash rates, driving simulator and on-road driving ability assessments, the relationship between disease severity, duration, medication dose and driving performance, the relationship between driving and neuropsychological test performance, and the effect of dopaminergic medications on driving. While it provides a current overview of the ongoing research, more comprehensive research is required for the full and proper development of policies and guidelines for assessing fitness to drive in PD.

πŸ“œ SIMILAR VOLUMES

Current Status of Symptomatic Medical Th
Current Status of Symptomatic Medical Therapy in Parkinson’s Disease
✍ Stewart A. Factor πŸ“‚ Article πŸ“… 2008 πŸ› Springer-Verlag 🌐 English βš– 153 KB

Symptomatic medical therapies for Parkinson's disease (PD) have been disease modifying and have led to improvement in daily function, quality of life, and survival. For 40 years, these therapies have been primarily dopaminergic, and currently include the dopamine (DA) precursor levodopa (LD), DA ago

Predictors of driving assessment outcome
Predictors of driving assessment outcome in Parkinson's disease
✍ Charles J. Worringham; Joanne M. Wood; Graham K. Kerr; Peter A. Silburn πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 68 KB πŸ‘ 1 views

## Abstract This study evaluated selected clinical and functional tests as predictors of driving safety outcomes in Parkinson's disease (PD) patients. A total of 25 PD patients and 21 age‐matched controls, all regular drivers, underwent neurological evaluation and assessment of cognitive, visual, a

Driving assessment in Parkinson's diseas
Driving assessment in Parkinson's diseaseβ€”A novel predictor of performance?
✍ Richard Cordell; Hoe C. Lee; Andrew Granger; Barry Vieira; Andy H. Lee πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 113 KB πŸ‘ 1 views

## Abstract Clinical symptoms of Parkinson's disease (PD) can make driving hazardous. The removal of the privilege to drive reduces independence; nevertheless, to protect public safety, medical practitioners require reliable screening tools to decide whether a PD driver should be on the road. The a

Levodopa in the treatment of Parkinson's
Levodopa in the treatment of Parkinson's disease: Current controversies
πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 27 KB πŸ‘ 1 views

## Abstract The original article to which this Erratum refers was published in the September, 2004 issue of __Movement__ Disorders (2004) 19 (9) 997–1005.

Levodopa in the treatment of Parkinson's
Levodopa in the treatment of Parkinson's disease: Current controversies
✍ C. Warren Olanow; Yves Agid; Yoshi Mizuno; Alberto Albanese; U. Bonucelli; Phili πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 94 KB πŸ‘ 1 views

## Abstract Levodopa is the most effective symptomatic agent in the treatment of Parkinson's disease (PD) and the β€œgold standard” against which new agents must be compared. However, there remain two areas of controversy: (1) whether levodopa is toxic, and (2) whether levodopa directly causes motor